TP53 and prostate carcinoma: Using a CLIA-compatible whole-transcriptome assay, the investigators computed 57 published expression signatures, including Decipher (commercial 22-gene prostate-cancer genomic classifier), PAM50–luminal, proliferation, PTEN-loss, and TP53-loss scores, and tested these against failure-free and OS in multivariable Cox models.